When does rucaparib’s patent protection expire in the EU?
I don’t have enough provided information to state a specific rucaparib patent expiration date in the EU. Patent terms in Europe depend on the exact patent family (and its priority date), whether the term is extended, and whether the relevant protection is a patent, an SPC (supplementary protection certificate), or both.
What should you check to find the exact EU expiration date for rucaparib?
To determine the real “expiration” date you likely care about (generic/biosimilar market entry timing), you usually need both:
- The patent family covering rucaparib (and its claims scope)
- Any EU SPC(s) tied to the marketing authorization for rucaparib, since SPCs can extend protection beyond the base patent term
Why SPCs matter for rucaparib in Europe
In the EU, a base patent can expire earlier than the effective market exclusivity if an SPC is in place. Effective protection timing is often the latest expiry among the relevant patents and SPCs that block competitors for the applicable indication/product.
Which “expiration” date do people mean in practice?
Searchers often mean one of these (they can differ):
- Expiry of the underlying patent term (base patent)
- Expiry of any SPC (often extends exclusivity)
- Expiry of data/exclusivity periods (regulatory marketing protection, separate from patents)
- A later “last in” expiry based on multiple overlapping patents/SPCs
If you tell me one detail, I can give a concrete date
If you share any of the following, I can pinpoint the likely expiry more precisely (and explain what it blocks):
- The marketed EU product name (brand) and strength (if relevant)
- The specific indication you care about (e.g., ovarian cancer maintenance vs other indications)
- Any patent/SPC number or a link to the EU register you’re using (EMA/EP register/EPO/“patent” page)
Sources
No sources were provided with your question, so I can’t cite an EU rucaparib patent expiration date.